Fusion of the Paired Box 3 (*PAX3*) and Myocardin (*MYOCD*) Genes in Pediatric Rhabdomyosarcoma

IOANNIS PANAGOPOULOS¹, LUDMILA GORUNOVA¹, KRISTIN ANDERSEN¹, MARIUS LUND-IVERSEN², SVETLANA TAFJORD², FRANCESCA MICCI¹ and SVERRE HEIM^{1,3}

¹Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;

²Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;

³Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

Abstract. *Background/Aim:* Fusions of the paired box 3 gene (*PAX3* in 2q36) with different partners have been reported in rhabdomyosarcomas and biphenotypic sinonasal sarcomas. We herein report the myocardin (*MYOCD* on 17p12) gene as a novel *PAX3*-fusion partner in a pediatric tumor with adverse clinical outcome. *Materials and Methods:* A rhabdomyosarcoma found in a 10-year-old girl was studied using a range of genetic methodologies. *Results:* The karyotype of the tumor cells was 48,XX,add(2)(q11),+del(2)(q35),add(3)(q?25),-7,del(8)(p21),-15,add(17)(p11),+20,+der(?)t(?;15)(?;q15),+mar[8]/46,XX[2]. Fluorescence in situ hybridization detected *PAX3* rearrangement whereas array comparative genomic hybridization revealed genomic imbalances affecting hundreds of genes, including *MYCN*, *MYC*, *FOXO3*, and the tumor suppressor gene *TP53*. A *PAX3-MYOCD* fusion transcript was found by RNA sequencing and confirmed by Sanger sequencing. *Conclusion:* The investigated rhabdomyosarcoma carried a novel *PAX3-MYOCD* fusion gene and extensive additional aberrations affecting the allelic balance of many genes, among them *TP53* and members of *MYC* and *FOXO* families of transcription factors.

Alveolar rhabdomyosarcomas are cytogenetically characterized by the specific chromosome translocations t(2;13)(q36;q14)

and t(1;13)(p36;q14) (1-4). The t(2;13)(q36;q14) results in fusion of the paired box 3 (*PAX3*) gene from 2q36 with the forkhead box O1 gene (*FOXO1*, also known as *FKHR*) from 13q14 (5-7), whereas t(1;13)(p36;q14) fuses the paired box 7 (*PAX7*) gene from 1p36 with *FOXO1* (8). The above-mentioned chromosome aberrations and their corresponding fusion genes are found in 80% of alveolar rhabdomyosarcomas (9). In the remaining 20%, fusions of *PAX3* with the genes *FOXO4* (also known as *AFX*, in Xq13), nuclear receptor coactivator 1 (*NCOA1*, in 2p23), nuclear receptor coactivator 2 (*NCOA2*, in 8q13) or INO80 complex subunit D (*INO80D*, in 2q33) were found (9-12).

Apart from alveolar rhabdomyosarcomas, *PAX3-FOXO1*, *PAX3-NCOA1*, and fusion of *PAX3* with the mastermind-like transcriptional coactivator 3 gene (*MAML3*, from 4q31.1; recombination occurs through a 2q35;4q31-chromosomal translocation) were also detected in biphenotypic sinonasal sarcomas (13-16). Furthermore, a *PAX3-NCOA2* fusion was reported in embryonal rhabdomyosarcoma (11, 17).

In the present study, we report the finding in a pediatric rhabdomyosarcoma of a novel fusion of *PAX3* with the myocardin (*MYOCD*) gene which maps to 17p12 and codes for a smooth and cardiac muscle-specific transcriptional coactivator of the serum response factor.

Materials and Methods

Ethics statement. The study was approved by the Regional Ethics Committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norge, <http://helseforskning.etikkom.no>). All patient information has been de-identified.

Case description. The patient was a ten-year-old girl with an advanced stage of rhabdomyosarcoma. The tumor presented as a pelvic mass with spreading to pelvic and abdominal lymph nodes, several pelvic and abdominal viscera, and tumorous nodules within the abdominal cavity. Examination of a diagnostic biopsy showed a

This article is freely accessible online.

Correspondence to: Ioannis Panagopoulos, Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, PO Box 4954 Nydalen, NO-0424 Oslo, Norway. Tel: +47 22782362, e-mail: ioannis.panagopoulos@rr-research.no

Key Words: Pediatric, rhabdomyosarcoma, chromosome translocation, *PAX3*, *MYOCD*, *PAX3-MYOCD* fusion gene.

malignant, poorly differentiated, round cell tumor with solid and alveolar growth patterns (Figure 1A-C). The tumor cells were loosely arranged in sheets surrounded by fibrous septa (Figure 1A-C). Examination of the surgical specimen revealed a tumor showing little effect of chemotherapy. The histology was heterogeneous but large areas displayed alveolar morphology, solid tumor growth, a spindle cell component, and tumor nests (Figure 1D-F). Immunohistochemistry revealed strong expression of desmin, transcription factor AP-2 beta (TFAP2B, also known as AP-2beta, Figure 1G), and myogenin (MYOG, also known as MYF4, Figure 1H); the latter with positivity in nearly 100% of tumor cells. FISH analysis with separate probes for the *PAX3* (2q36.1), *PAX7* (1p36.13), and *FOXO1* (13q14) genes showed rearrangement of *PAX3* whereas *PAX7* and *FOXO1* were intact.

G-Banding, karyotyping, and fluorescence in situ hybridization (FISH). The methodology for cytogenetic investigation of solid tumors was described elsewhere (18). In brief, fresh tissue from a representative area of the tumor was disaggregated mechanically and enzymatically with collagenase II (Worthington, Freehold, NJ, USA). The resulting cells were cultured and harvested using standard techniques. Chromosome preparations were G-banded with Wright's stain (Sigma Aldrich; St Louis, MO, USA) and examined. Metaphases were analyzed and karyograms prepared using the CytoVision computer assisted karyotyping system (Leica Biosystems, Newcastle, UK). FISH was performed on interphase nuclei using the CytoCell *PAX3* breakapart FISH probe (Cytocell, Oxford Gene Technology, Begbroke, Oxfordshire, UK). It consists of a telomeric green 168kb probe and a centromeric red 124kb probe, which are positioned on each side of the *PAX3* gene. Fluorescent signals were captured and analyzed using the CytoVision system (Leica Biosystems).

Array comparative genomic hybridization (aCGH) analysis. Genomic DNA from tumor sample was extracted using the Maxwell RSC Instrument and the Maxwell RSC Tissue DNA Kit (Promega, Madison, WI, USA) and quantified with the Quantus fluorometer and the QuantiFluor ONE dsDNA System (Promega). Promega's human genomic female DNA was used as reference DNA. aCGH was performed using CytoSure array products (Oxford Gene Technology) as previously described (19). Thus, the CytoSure Genomic DNA Labelling Kit was used for labelling of 1 µg of each of tumor and reference DNA, and the CytoSure Cancer +SNP array was used for hybridization. The slides were scanned in an Agilent scanner using the Agilent Feature Extraction Software (version 10.7.3.1). Data were analyzed with the CytoSure Interpret analysis software (version 4.9.40). Annotations were based on human genome build 19.

RNA sequencing. Total RNA was extracted from frozen tumor tissue adjacent to that used for cytogenetic analysis and histologic examination using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). One µg of total RNA was sent to the Genomics Core Facility at the Norwegian Radium Hospital, Oslo University Hospital for high-throughput paired-end RNA-sequencing. Fusion transcripts were found using the FusionCatcher software (20, 21).

Reverse transcription (RT) PCR and Sanger sequencing analyses. The primers used for PCR amplification and Sanger sequencing analysis are given in Table I. The methods for cDNA synthesis, RT-

PCR amplification, and Sanger sequencing were described elsewhere (19). For the first, outer PCR amplification, the primer combination PAX3-1352F1/MYOCOD-2687R1 was used whereas the primer combination PAX3-1374F1/MYOCOD-2664R1 was used for the second, inner PCR. The basic local alignment search tool (BLAST) was used to compare sequences obtained by Sanger sequencing with the NCBI reference sequences NM_181457.4 (*PAX3*) and NM_153604.3 (*MYOCOD*) (22).

Results

G-banding analysis of short-term cultured tumor cells yielded the karyotype 48,XX,add(2)(q11),+del(2)(q35),add(3)(q?25),-7,del(8)(p21),-15,add(17)(p11),+20,+der(?)t(?;15)(?:q15),+mar[8]/46,XX[2] (Figure 2).

FISH analysis with a breakapart probe for *PAX3* (Figure 3A) showed a green signal (telomeric probe) and two red signals (centromeric probe) in 80 out of 100 examined interphase nuclei (Figure 3B).

aCGH confirmed trisomy for chromosome 20 and showed gains and losses on various parts of chromosomes 2, 3, 6, 7, 8, 9, 10, 17, and 19 (Table II, Figure 4A) which affected hundreds of genes. On chromosome 2, a 1.34Mb size region on 2p24.3-p24.2 (Chr2:15991412-17336196) was found to have seven copies (Table II, Figure 4B). This region contained the MYCN opposite strand/antisense RNA (*MYCNOS*), MYCN proto-oncogene (*MYCN*) and a gene with the official name CYFIP related Rac1 interactor A (*CYRIA* alias *FAM49A*). The area of the *PAX3* gene on 2q36.1 (chr2:223,064,606-223,163,715) showed a complex pattern of gains and losses (Figure 4C). An extra copy was seen for the part of *PAX3* between exon 1 and exon 7, whereas the part of the gene between exons 8 and 10 was heterozygously lost (Figure 4C). The red centromeric probe of the *PAX3* breakapart FISH probe was found to map to an area which showed gain of one copy (Figure 4C). This might be the explanation for the two red signals seen in FISH-examined interphase nuclei (Figure 3B).

An extra copy was found for each of the genes *MYC* (paralog to *MYCN*; on 8q24.21, position chr8:128,748,315-128,753,680) and forkhead box O3 (*FOXO3*, paralog to *FOXO1*; on 6q21, position chr6:108,882,069-109,005,971) (Table II).

On chromosome 17 (Figure 4D), within the 17p13.3-p12 region which had loss of one copy, the MAX network transcriptional repressor (*MNT*) and tumor protein p53 (*TP53*, on 17p13.1, chr17:7,571,720-7,590,868) genes were mapped (Figure 4D). With regard to *MYOCOD* (on 17p12, position chr17:12,569,207-12,670,651), the number of aCGH probes was inadequate to draw certain conclusions (Figure 4E). In 17p12-p11.1, an extra copy of the *FOXO3B* gene was seen (chr17:18,570,942-18,585,627).

RNA sequencing analysis using FusionCatcher detected a fusion transcript between *PAX3* from 2q36 and *MYOCOD* from

Figure 1. Microscopic examination of the pediatric rhabdomyosarcoma. (A, B, and C) Tumor with alveolar growth pattern showing loosely arranged tumor cells surrounded by fibrous septa. (D) Tumor with spindle cell pattern. (E) Tumor with mixed growth pattern. (F) Tumor in nests. (G) Transcription factor AP-2 beta showed diffuse and strong expression in tumor nuclei. (H) Myogenin showed strong positive staining in nearly 100% of tumor nuclei.

Figure 2. Cytogenetic examination of the pediatric rhabdomyosarcoma. Representative karyogram showing the abnormal karyotype 48,add(2)(q11),+del(2)(q35),add(3)(q25),-7,del(8)(p21),-15,add(17)(p11),+20,+der(?)t(?;15)(?;q15),+mar.

17p12: CAACCCATGAACCCACCATTTGGCAATGGC CTCTCACCTCAG*CAAATGACCCGGAGTCAGCAGATG GATGAACTCCTGGACGTGC. The presence of this *PAX3-MYOC*D fusion transcript was confirmed by RT-PCR together with Sanger sequencing (Figure 5A and 5B). In the *PAX3-MYOC*D fusion transcript, exon 7 of *PAX3* (nt 1556 in reference sequence NM_181457.4) was fused in frame with exon 12 of *MYOC*D (nt 2487 in reference sequence NM_153604.3).

Based on the *PAX3* reference sequence NM_181457.4/ NP_852122.1 and *MYOC*D reference sequence NM_153604.3/ NP_705832.1, the *PAX3-MYOC*D fusion transcript would be expected to code for a 600 amino acid residue (aa) chimeric protein composed of the first 390 aa from the *PAX3* protein (1-390 from NP_852122.1) and the last 210 aa of *MYOC*D protein containing the transactivation domain of the latter (729-938 from NP_705832.1) (Figure 5C).

Discussion

To the best of our knowledge, this is the first time that a fusion between *PAX3* and *MYOC*D is described. Because both genes, *PAX3* on 2q36 and *MYOC*D on 17p12, are transcribed from telomere to centromere, a simple balanced translocation should be enough to generate a functional *PAX3-MYOC*D fusion gene on the der(17). However, karyotyping of the tumor cells indicated complex rearrangements and the aberrations seen could not be described more accurately than del(2)(q35) and add(17)(p11). Searching the “Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer” (updated on April 15, 2021), we did not find any rhabdomyosarcoma (alveolar, embryonal, pleomorphic, spindle cell/sclerosing or rhabdomyosarcoma not otherwise specified) carrying a t(2;17)(q36;p12) chromosome aberration nor any tumors with a *PAX3-MYOC*D fusion (23). Among the

Figure 3. Fluorescence in situ hybridization (FISH) analysis of the pediatric rhabdomyosarcoma using a commercial PAX3 breakapart probe. (A) Diagram showing the proximal (red) and distal (green) parts of the PAX3 breakapart probe. The neighbor gene sphingosine-1-phosphate phosphatase 2 (SGPP2) and the genetic markers D2S102, D2S2599, D2S313, and D2S2300 are also shown. (B) FISH on interphase nucleus with the PAX3 breakapart probe.

Table I. Primers used for polymerase chain reaction amplification and Sanger sequencing analyses.

Name: Sequence (5'→3')	Reference sequence: Position	Gene name (gene symbol)	Chromosome band
PAX3-1352F1: TCCCAGCAGCACCGTTCACAGA	NM_181457.4: 1352-1373	Paired box 3 (PAX3)	2q36
PAX3-1374F1: CCTCAACCGCTTCCTCCAAGCA	NM_181457.4: 1374-1395	Paired box 3 (PAX3)	2q36
MYOCD-2687R1: TCACTGTCGGTGGCATAGGGATCA	NM_153604.3: 2710-2687	Myocardin (MYOCD)	17p12
MYOCD-2664R1: AAGGGGATCTGGCTGCCTGAAGA	NM_153604.3: 2686-2664	Myocardin (MYOCD)	17p12

237 rhabdomyosarcomas with an abnormal karyotype in the Mitelman Database, ten had cytogenetic aberrations affecting the short arm of chromosome 17 (23): an alveolar rhabdomyosarcoma carried a t(4;17)(q11;p11) (24), three embryonal and two pleomorphic rhabdomyosarcomas showed

add(17)(p11) (24-28), a rhabdomyosarcoma not otherwise specified had del(17)(p12) (29), and two embryonal and one pleomorphic rhabdomyosarcoma had aberrations involving band 17p13 (26, 30). Although the possibility of a cryptic rearrangement cannot be excluded, the above-mentioned data

Figure 4. Array comparative genomic hybridization (aCGH) analysis of the pediatric rhabdomyosarcoma. (A) Whole genome aCGH showing trisomy for chromosome 20 and gains as well as losses from parts of chromosomes 2, 3, 6, 7, 8, 9, 10, 17, and 19. (B) Regions of chromosome 2 with gains and losses. The positions of the genes MYCNOS, MYCN, CYRIA, and PAX3 are shown. (C) The region around PAX3 showing both gains and losses. The position of the red centromeric and the green telomeric probes of the FISH PAX3 breakapart probe are also shown. The genomic area of PAX3 encompassing exons 1 to 7 is gained whereas the PAX3 area encompassing exons 8 to 10 is heterozygously lost. The FISH red centromeric probe maps to an area which has an extra copy (gain). (D) Regions of chromosome 17 with gain and loss. The positions of the genes MNT, TP53, MYOCD, and FOXO3B are shown. (E) The region around the MYOCD showing loss of a copy at the telomeric area (loss) and gain of a copy near the centromere. The few aCGH probes for MYOCD are inadequate to draw any certain conclusion as to possible copy number change of MYOCD.

Table II. Results of array comparative genomic hybridization (aCGH) analysis of the pediatric rhabdomyosarcoma.

Cytogenetic location	Position on GRCh37/hg19 assembly	Size	Gain/Loss	Copy number
2p25.3-p24.3	Chr2:28080-15666840	15.64Mb	Gain	3
2p24.3-p24.2	Chr2:15991412-17336196	1.34Mb	Gain	7
2p24.2-p11.2	Chr2:17400700-90112889	73.11Mb	Gain	3
2q33.2-q35	Chr2:204598942-220738051	16.14Mb	Gain	3
2q35	Chr2:220737992-221483616	745.62Kb	Loss	1
2q36.1	Chr2:221521686-222895162	1.37Mb	Gain	3
2q36.1	Chr2:222928374-223076308	147.94Kb	Loss	1
2q36.1	Chr2:223084848-223163460	78.61Kb	Gain	3
2q36.1	Chr2:223176619-223256245	79.63Kb	Loss	1
3q24-q27.2	Chr3:148748271-185798988	37.05Mb	Gain	3
6q21	Chr6:108579217-109235546	656.33Kb	Gain	3
7p22.3-p21.3	Chr7:55649-10831224	10.78Mb	Loss	1
7p21.3-p11.2	Chr7:10633862-57924753	47.29Mb	Loss	1
7q11.1-q22.1	Chr7:61300518-102175773	40.88Mb	Loss	1
7q22.1-q36.3	Chr7:102346891-159006977	56.66Mb	Gain	3
8p23.3-p23.1	Chr8:31167-11369498	11.34Mb	Loss	1
8p21.2-p21.1	Chr8:25519631-28783983	3.26Mb	Gain	3
8p12-p11.1	Chr8:35041928-43210505	8.17Mb	Gain	3
8q13.3	Chr8:71311272-72740821	1.43Mb	Gain	3
8q21.11-q21.13	Chr8:74279304-80124748	5.85Mb	Gain	3
8q23.1-q24.11	Chr8:108369778-117978907	9.61Mb	Gain	3
8q24.13-q24.3	Chr8:125815021-146238409	20.42Mb	Gain	3
9q33.3-q34.3	Chr9:127044087-141102523	14.06Mb	Gain	3
10q22.1-q22.2	Chr10:72766561-75476122	2.71Mb	Gain	3
17p13.3-p12	Chr17:89086-12580027	12.49Mb	Loss	1
17p12-p11.1	Chr17:12689797-22219743	9.53Mb	Gain	3
17q11.1-q21.33	Chr17:25294244-48947156	23.65Mb	Gain	3
19q13.43	Chr19:57479515-57672410	192.9Kb	Gain	3
20p13-p11.1	Chr20:72367-26257880	26.19Mb	Gain	3
20q11.21-q13.33	Chr20:29453459-62952205	33.5Mb	Gain	3

indicate that straightforward two-way aberrations such as t(2;17)(q36;p12) are rare causes of *PAX3-MYOC*D fusions in rhabdomyosarcomas.

In the *PAX3-MYOC*D chimeric transcript, the point of fusion in *PAX3* was exon 7. The same fusion point was also seen in the transcripts *PAX3-FOXO1*, *PAX3-INOD88*, *PAX3-NCOA2*, the transcript 2 of *PAX3-NCOA1*, and *PAX3-MAML3* (5-7, 9-17). All these fusion genes would code for chimeric transcription factors that have the N-terminal part of *PAX3* (aa 1-390 of NP_852122.1). This N-terminal part contains the highly conserved paired box domain (position 34-159) that binds to DNA sequences related to the TCACGC/G motif, followed by the microfibril-associated/pre-mRNA processing region (position 163-286), the homeobox domain (position 222-275), and the paired box protein 7 domain (347-390) (31). The C-terminal part of the various 3'-end partner genes contains the transactivation domains of the chimeric transcription factors (5-7, 9-17).

In vitro studies have shown that the *PAX3-FOXO1*, *PAX3-NCOA1*, *PAX3-NCOA2*, and *PAX3-MAML3* chimeric proteins are much stronger transcriptional activators than

PAX3 (10, 16, 17, 32-34). Moreover, the *PAX3-FOXO1* and *PAX3-NCOA2* proteins were found to simultaneously initiate myogenesis and inhibit terminal differentiation, which is why they have been called “pangenes” in tumorigenesis (17, 35).

In a similar manner to what happens with the above-mentioned *PAX3*-fusion genes, the *PAX3-MYOC*D fusion is predicted to code for a chimeric transcription factor composed of the N-terminal part, with the DNA binding domain, of *PAX3* and the C-terminal transactivation domain of *MYOC*D (Figure 5C). *MYOC*D is expressed in heart, aorta, and smooth muscle cell-rich tissues such as the stomach, bladder, small intestine, colon, and uterus (36, 37). It codes for a transcriptional co-activator of serum response factor with many functional domains, one of which is a transactivation domain at the end of the protein (36, 38, 39). *MYOC*D regulates the development and differentiation of cardiomyocytes and has been reported to be a master regulator of smooth muscle gene expression (36, 37, 40). The myocardin gene was found highly amplified in non-uterine (41, 42) but down-regulated in uterine leiomyosarcomas (43). Exogenous expression of myocardin in uterine leiomyosarcoma cells resulted in growth arrest and

Figure 5. Molecular genetic analyses of the pediatric rhabdomyosarcoma. (A) Gel electrophoresis showing the amplified PAX3-MYOC D cDNA fragment with nested PCR using the primer combination PAX3-1374F1/MYOC D-2664R1 (lane 1). M: GeneRuler 1 Kb Plus DNA ladder (ThermoFisher Scientific). (B) Partial sequence chromatograms of the cDNA amplified fragment showing the junction position of the PAX3 and MYOC D genes (vertical dotted line). In the PAX3-MYOC D fusion transcript, exon 7 of PAX3 (nt 1556 in reference sequence NM_181457.4) was fused in frame with exon 12 of MYOC D (nt 2487 in reference sequence NM_153604.3). (C) The 600 amino acid (aa) residues of the PAX3-MYOC D protein is composed of the first 390 aa (in yellow) from PAX3 (1-390 from NP_852122.1) and the last 210 aa (in green) from MYOC D which contains the transactivation domain of MYOC D (729-938 from NP_705832.1).

differentiation to smooth muscle cells (43). Similar results were also found for other sarcoma cells, *i.e.*, MYOC D expression resulted in differentiation and growth inhibition. Repression of MYOC D expression in normal fibroblasts increased their proliferation potential indicating that MYOC D acts as a tumor suppressor (44).

aCGH detected submicroscopic gains and losses from nine chromosomes (Table II, Figure 4A) affecting the copy number status of hundreds of genes. Among them are paralogs of oncogenes MYCN (seven copies), MYC (three copies), as well as the MNT gene (one copy) which codes for a functional antagonist of MYC (45-47). Thus, the MYC/MYCN pathway was affected (48-51). Amplification of MYCN is a well-known genetic aberration in alveolar rhabdomyosarcomas and is associated with poor prognosis (52-55). Amplification of MYC was reported in both alveolar and embryonal rhabdomyosarcoma cell lines and tumors (56, 57). Furthermore, only one allele of the tumor suppressor TP53 gene was found in the tumor we examined (Figure 4D).

Mutations of TP53 in alveolar rhabdomyosarcomas carrying the PAX3-FOXO1 fusion are extremely rare but lethal (12, 58, 59). aCGH also detected an extra copy of the FOXO3 gene (6q21) which is a paralog of FOXO1 involved in carcinogenesis (60-63). FOXO3 together with FOXO1 (in 13q14.11), FOX3B (in 17p11.2), FOXO4 (in Xq13.1), and FOXO6 (in 1p34.2) comprise the FOXO family of transcription factors which regulate a plethora of signal pathways; their deregulation plays a key role in cancer (60-63). Both downregulation and overexpression of FOXO3 was reported in cancer and found associated with increased tumor aggressiveness and unfavorable clinical outcome (62). Low expression of FOXO3 was associated with poor prognosis in ovarian cancer, glioma, and clear-cell renal carcinoma (64-66), whereas overexpression of the gene was associated with aggressive phenotype and poor clinical outcome in glioblastoma and hepatocellular carcinoma (67, 68). FOXO3 fusion genes were also reported in leukemias and solid tumors. A t(6;11)(q21;q23) chromosome translocation in leukemia

resulted in fusion of the lysine methyltransferase 2A (*KMT2A*) gene with *FOXO3* coding for a *KMT2A-FOXO3* chimeric protein (69, 70). In two myoepithelioma-like hyalinizing epithelioid tumors of the hand, fusion of *OGT* (in Xq13.1, official full name: O-linked N-acetylglucosamine (GlcNAc) transferase) with *FOXO3* was reported (71). Recently, the *OGT-FOXO1* and *OGT-FOXO4* fusion genes were found in tumors with similar pathological features (72, 73) suggesting that fusion of *OGT* with members of the FOXO family of transcription factors might characterize this type of tumor.

In summary, we present here a pediatric rhabdomyosarcoma carrying a novel *PAX3-MYOD* fusion gene and extensive genomic imbalances which affect the allelic balance of many genes, among them members of the *MYC* and *FOXO* families of transcription factors, as well as the tumor suppressor gene *TP53*. The result was lethal in the described case.

Conflicts of Interest

The Authors declare that they have no conflicts of interest with regard to this study.

Authors' Contributions

IP designed and supervised the research, performed molecular genetic experiments and bioinformatics analysis, and wrote the article. LG performed cytogenetic analysis. KA performed molecular genetic experiments and evaluated the data. ML-I performed pathological examination. ST performed pathological examination. FM evaluated the cytogenetic data. SH evaluated the cytogenetic data, assisted with experimental design, and helped write the article. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants from Radiumhospitalets Legater.

References

- Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Houghton JA and Green AA: A specific chromosomal abnormality in rhabdomyosarcoma. *Cytogenet Cell Genet* 45(3-4): 148-155, 1987. PMID: 3691179. DOI: 10.1159/000132446
- Biegel JA, Meek RS, Parmiter AH, Conard K and Emanuel BS: Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. *Genes Chromosomes Cancer* 3(6): 483-484, 1991. PMID: 1663783. DOI: 10.1002/gcc.2870030612
- Douglass EC, Rowe ST, Valentine M, Parham DM, Berkow R, Bowman WP and Maurer HM: Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. *Genes Chromosomes Cancer* 3(6): 480-482, 1991. PMID: 1777415. DOI: 10.1002/gcc.2870030611
- Douglass EC, Shapiro DN, Valentine M, Rowe ST, Carroll AJ, Raney RB, Ragab AH, Abella SM and Parham DM: Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. *Med Pediatr Oncol* 21(2): 83-87, 1993. PMID: 8433683. DOI: 10.1002/mpo.2950210202
- Barr FG, Galili N, Holick J, Biegel JA, Rovera G and Emanuel BS: Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 3(2): 113-117, 1993. PMID: 8098985. DOI: 10.1038/ng0293-113
- Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G and Barr FG: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 5(3): 230-235, 1993. PMID: 8275086. DOI: 10.1038/ng1193-230
- Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW: Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. *Cancer Res* 53(21): 5108-5112, 1993. PMID: 8221646.
- Davis RJ, D'Cruz CM, Lovell MA, Biegel JA and Barr FG: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 54(11): 2869-2872, 1994. PMID: 8187070.
- Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA and Sorensen PH: Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. *Cancer Res* 62(16): 4704-4710, 2002. PMID: 12183429.
- Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Bühlmann P, Niggli FK and Schäfer BW: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. *Cancer Res* 64(16): 5539-5545, 2004. PMID: 15313887. DOI: 10.1158/0008-5472.CAN-04-0844
- Sumegi J, Streblov R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A and Bridge JA: Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. *Genes Chromosomes Cancer* 49(3): 224-236, 2010. PMID: 19953635. DOI: 10.1002/gcc.20731
- Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS and Khan J: Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov* 4(2): 216-231, 2014. PMID: 24436047. DOI: 10.1158/2159-8290.CD-13-0639
- Fritchie KJ, Jin L, Wang X, Graham RP, Torbenson MS, Lewis JE, Rivera M, Garcia JJ, Schembri-Wismayer DJ, Westendorf JJ, Chou MM, Dong J and Oliveira AM: Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. *Histopathology* 69(6): 930-936, 2016. PMID: 27454570. DOI: 10.1111/his.13045
- Huang SC, Ghossein RA, Bishop JA, Zhang L, Chen TC, Huang HY and Antonescu CR: Novel PAX3-NCOA1 fusions in biphenotypic sinonasal sarcoma with focal rhabdomyoblastic differentiation. *Am J Surg Pathol* 40(1): 51-59, 2016. PMID: 26371783. DOI: 10.1097/PAS.0000000000000492
- Wong WJ, Lauria A, Hornick JL, Xiao S, Fletcher JA and Marino-Enriquez A: Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. *Genes Chromosomes Cancer* 55(1): 25-29, 2016. PMID: 26355893. DOI: 10.1002/gcc.22295

- 16 Wang X, Bledsoe KL, Graham RP, Asmann YW, Viswanatha DS, Lewis JE, Lewis JT, Chou MM, Yaszemski MJ, Jen J, Westendorf JJ and Oliveira AM: Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. *Nat Genet* 46(7): 666-668, 2014. PMID: 24859338. DOI: 10.1038/ng.2989
- 17 Yoshida H, Miyachi M, Sakamoto K, Ouchi K, Yagyu S, Kikuchi K, Kuwahara Y, Tsuchiya K, Imamura T, Iehara T, Kakazu N, Hojo H and Hosoi H: PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells. *Oncogene* 33(49): 5601-5608, 2014. PMID: 24213582. DOI: 10.1038/nc.2013.491
- 18 Panagopoulos I, Gorunova L, Lund-Iversen M, Andersen K, Andersen HK, Lobmaier I, Bjerkehaugen B and Heim S: Cytogenetics of spindle cell/pleomorphic lipomas: Karyotyping and FISH analysis of 31 tumors. *Cancer Genomics Proteomics* 15(3): 193-200, 2018. PMID: 29695401. DOI: 10.21873/cgp.20077
- 19 Panagopoulos I, Gorunova L, Andersen K, Lund-Iversen M, Lobmaier I, Micci F and Heim S: *NDRG1-PLAG1* and *TRPS1-PLAG1* fusion genes in chondroid syringoma. *Cancer Genomics Proteomics* 17(3): 237-248, 2020. PMID: 32345665. DOI: 10.21873/cgp.20184
- 20 Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumägi A and Kallioniemi O: Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms. *PLoS One* 7(10): e48745, 2012. PMID: 23119097. DOI: 10.1371/journal.pone.0048745
- 21 Nicorici D, Satalan H, Edgren H, Kangaspeska S, Murumagi A, Kallioniemi O, Virtanen S and Kikku O: FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data. *bioRxiv*, 2014. DOI: 10.1101/011650
- 22 Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ: Basic local alignment search tool. *J Mol Biol* 215(3): 403-410, 1990. PMID: 2231712. DOI: 10.1016/S0022-2836(05)80360-2
- 23 Mitelman F, Johansson B and Mertens F: Mitelman database of chromosome aberrations and gene fusions in cancer. 2021. Available at: <https://mitelmanandatabase.isb-cgc.org/> [Last accessed on May 21, 2021]
- 24 Kullendorff CM, Donner M, Mertens F and Mandahl N: Chromosomal aberrations in a consecutive series of childhood rhabdomyosarcoma. *Med Pediatr Oncol* 30(3): 156-159, 1998. PMID: 9434823. DOI: 10.1002/(sici)1096-911x(199803)30:3<156::aid-mpo5>3.0.co;2-g
- 25 Van den Berg E, Molenaar WM, Hoekstra HJ, Kamps WA and de Jong B: DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas. *Mod Pathol* 5(5): 505-514, 1992. PMID: 1344814.
- 26 Gordon T, McManus A, Anderson J, Min T, Swansbury J, Pritchard-Jones K, Shipley J, United Kingdom Children's Cancer Study Group and United Kingdom Cancer Cytogenetics Group: Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. *Med Pediatr Oncol* 36(2): 259-267, 2001. PMID: 11452933. DOI: 10.1002/1096-911X(20010201)36:2<259::AID-MPO1063>3.0.CO;2-K
- 27 Li G, Ogose A, Kawashima H, Umezumi H, Hotta T, Tohyama T, Ariizumi T and Endo N: Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. *Cancer Genet Cytogenet* 192(1): 1-9, 2009. PMID: 19480930. DOI: 10.1016/j.cancergencyto.2009.02.011
- 28 Walther C, Mayrhofer M, Nilsson J, Hofvander J, Jonson T, Mandahl N, Øra I, Gisselsson D and Mertens F: Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis. *Genes Chromosomes Cancer* 55(1): 3-15, 2016. PMID: 26482321. DOI: 10.1002/gcc.22285
- 29 Fletcher JA, Kozakewich HP, Hoffer FA, Lage JM, Weidner N, Tepper R, Pinkus GS, Morton CC and Corson JM: Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. *N Engl J Med* 324(7): 436-442, 1991. PMID: 1988828. DOI: 10.1056/NEJM199102143240702
- 30 Goldstein M, Meller I, Issakov J and Orr-Urtreger A: Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. *Neoplasia* 8(5): 332-343, 2006. PMID: 16790082. DOI: 10.1593/neo.05829
- 31 Boudjadi S, Chatterjee B, Sun W, Vemu P and Barr FG: The expression and function of PAX3 in development and disease. *Gene* 666: 145-157, 2018. PMID: 29730428. DOI: 10.1016/j.gene.2018.04.087
- 32 Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ 3rd and Barr FG: Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. *Oncogene* 11(1): 119-130, 1995. PMID: 7624119.
- 33 Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG and Rauscher FJ 3rd: The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. *Mol Cell Biol* 15(3): 1522-1535, 1995. PMID: 7862145. DOI: 10.1128/MCB.15.3.1522
- 34 Sublett JE, Jeon IS and Shapiro DN: The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. *Oncogene* 11(3): 545-552, 1995. PMID: 7630639.
- 35 Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX and Anderson MJ: PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. *Oncogene* 27(14): 2004-2014, 2008. PMID: 17922034. DOI: 10.1038/sj.onc.1210835
- 36 Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E, Krieg PA and Olson EN: Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. *Cell* 105(7): 851-862, 2001. PMID: 11439182. DOI: 10.1016/S0092-8674(01)00404-4
- 37 Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK and Parmacek MS: Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. *Mol Cell Biol* 23(7): 2425-2437, 2003. PMID: 12640126. DOI: 10.1128/MCB.23.7.2425-2437.2003
- 38 Miano JM: Myocardin in biology and disease. *J Biomed Res* 29(1): 3-19, 2015. PMID: 25745471. DOI: 10.7555/JBR.29.20140151
- 39 Xia XD, Zhou Z, Yu XH, Zheng XL and Tang CK: Myocardin: A novel player in atherosclerosis. *Atherosclerosis* 257: 266-278, 2017. PMID: 28012646. DOI: 10.1016/j.atherosclerosis.2016.12.002
- 40 Wang Z, Wang DZ, Pipes GC and Olson EN: Myocardin is a master regulator of smooth muscle gene expression. *Proc Natl Acad Sci USA* 100(12): 7129-7134, 2003. PMID: 12756293. DOI: 10.1073/pnas.1232341100
- 41 Pérot G, Derré J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault L, Guillou L, Terrier P and Aurias A: Strong smooth

- muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. *Cancer Res* 69(6): 2269-2278, 2009. PMID: 19276386. DOI: 10.1158/0008-5472.CAN-08-1443
- 42 Agaram NP, Zhang L, LeLoarer F, Silk T, Sung YS, Scott SN, Kuk D, Qin LX, Berger MF, Antonescu CR and Singer S: Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. *Genes Chromosomes Cancer* 55(2): 124-130, 2016. PMID: 26541895. DOI: 10.1002/gcc.22318
 - 43 Kimura Y, Morita T, Hayashi K, Miki T and Sobue K: Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells. *Cancer Res* 70(2): 501-511, 2010. PMID: 20068148. DOI: 10.1158/0008-5472.CAN-09-1469
 - 44 Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, Eden A and Rotter V: Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. *Cancer Cell* 11(2): 133-146, 2007. PMID: 17292825. DOI: 10.1016/j.ccr.2006.11.022
 - 45 Hurlin PJ, Zhou ZQ, Toyo-Oka K, Ota S, Walker WL, Hirotsune S and Wynshaw-Boris A: Evidence of mnt-myc antagonism revealed by mnt gene deletion. *Cell Cycle* 3(2): 97-99, 2004. PMID: 14712062.
 - 46 Wahlström T and Henriksson M: Mnt takes control as key regulator of the myc/max/mxd network. *Adv Cancer Res* 97: 61-80, 2007. PMID: 17419941. DOI: 10.1016/S0065-230X(06)97003-1
 - 47 Link JM and Hurlin PJ: The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. *Biochim Biophys Acta* 1849(5): 554-562, 2015. PMID: 24731854. DOI: 10.1016/j.bbagr.2014.04.004
 - 48 Ruiz-Pérez MV, Henley AB and Arsenian-Henriksson M: The MYCN protein in health and disease. *Genes (Basel)* 8(4): 113, 2017. PMID: 28358317. DOI: 10.3390/genes8040113
 - 49 Liu R, Shi P, Wang Z, Yuan C and Cui H: Molecular mechanisms of MYCN dysregulation in cancers. *Front Oncol* 10: 625332, 2021. PMID: 33614505. DOI: 10.3389/fonc.2020.625332
 - 50 Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM and Felsher DW: The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. *Nat Rev Clin Oncol*, 2021. PMID: 34508258. DOI: 10.1038/s41571-021-00549-2
 - 51 Lourenco C, Resette D, Redel C, Lin P, MacDonald AS, Ciaccio R, Kenney TMG, Wei Y, Andrews DW, Sunnerhagen M, Arrowsmith CH, Raught B and Penn LZ: MYC protein interactors in gene transcription and cancer. *Nat Rev Cancer* 21(9): 579-591, 2021. PMID: 34188192. DOI: 10.1038/s41568-021-00367-9
 - 52 Dias P, Kumar P, Marsden HB, Gattamaneni HR, Heighway J and Kumar S: N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. *Int J Cancer* 45(4): 593-596, 1990. PMID: 2323837. DOI: 10.1002/ijc.2910450403
 - 53 Dias P, Kumar P, Marsden H, Gattamaneni H, Heighway J and Kumar S: Alveolar rhabdomyosarcoma - primary and recurrent metastatic tumor has chromosomal translocation t(2-13)(q37-q14), amplified N-myc and is tumorigenic in nude-mice. *Int J Oncol* 1(1): 47-51, 1992. PMID: 21584508. DOI: 10.3892/ijo.1.1.47
 - 54 Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S and Squire J: MYCN gene amplification in rhabdomyosarcoma. *Cancer* 73(8): 2231-2237, 1994. PMID: 8156531. DOI: 10.1002/1097-0142(19940415)73:8<2231::aid-cnrcr2820730832>3.0.co;2-e
 - 55 Williamson D, Lu YJ, Gordon T, Sciort R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K and Shipley J: Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. *J Clin Oncol* 23(4): 880-888, 2005. PMID: 15681534. DOI: 10.1200/JCO.2005.11.078
 - 56 Kouraklis G, Triche TJ, Wesley R and Tsokos M: Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines. *Pediatr Res* 45(4 Pt 1): 552-558, 1999. PMID: 10203148. DOI: 10.1203/00006450-199904010-00015
 - 57 Zhang J, Song N, Zang D, Yu J, Li J, Di W, Guo R, Zhao W and Wang H: c-Myc promotes tumor proliferation and anti apoptosis by repressing p21 in rhabdomyosarcomas. *Mol Med Rep* 16(4): 4089-4094, 2017. PMID: 28765944. DOI: 10.3892/mmr.2017.7101
 - 58 Ognjanovic S, Martel G, Manivel C, Olivier M, Langer E and Hainaut P: Low prevalence of TP53 mutations and MDM2 amplifications in pediatric rhabdomyosarcoma. *Sarcoma* 2012: 492086, 2012. PMID: 22550420. DOI: 10.1155/2012/492086
 - 59 Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, Yohe ME, Sindiri S, Wei J, Wen X, Rudzinski ER, Barkauskas DA, Lo T, Hall D, Linardic CM, Hughes D, Jamal S, Jenney M, Chisholm J, Brown R, Jones K, Hicks B, Angelini P, George S, Chesler L, Hubank M, Kelsey A, Gatz SA, Skapek SX, Hawkins DS, Shipley JM and Khan J: Genomic classification and clinical outcome in rhabdomyosarcoma: A report from an international consortium. *J Clin Oncol* 39(26): 2859-2871, 2021. PMID: 34166060. DOI: 10.1200/JCO.20.03060
 - 60 Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. *Oncogene* 24(50): 7410-7425, 2005. PMID: 16288288. DOI: 10.1038/sj.onc.1209086
 - 61 Coomans de Brachène A and Demoulin JB: FOXO transcription factors in cancer development and therapy. *Cell Mol Life Sci* 73(6): 1159-1172, 2016. PMID: 26686861. DOI: 10.1007/s00018-015-2112-y
 - 62 Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in carcinogenesis. *Mol Cancer* 17(1): 104, 2018. PMID: 30045773. DOI: 10.1186/s12943-018-0856-3
 - 63 Jiramongkol Y and Lam EW: FOXO transcription factor family in cancer and metastasis. *Cancer Metastasis Rev* 39(3): 681-709, 2020. PMID: 32372224. DOI: 10.1007/s10555-020-09883-w
 - 64 Fei M, Zhao Y, Wang Y, Lu M, Cheng C, Huang X, Zhang D, Lu J, He S and Shen A: Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. *Cancer Invest* 27(1): 52-59, 2009. PMID: 19160093. DOI: 10.1080/07357900802146204
 - 65 Shi J, Zhang L, Shen A, Zhang J, Wang Y, Zhao Y, Zou L, Ke Q, He F, Wang P, Cheng C and Shi G: Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1. *J Neurooncol* 98(1): 57-69, 2010. PMID: 19911116. DOI: 10.1007/s11060-009-0045-8
 - 66 Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y, Ai Q, Zhang P, Song EL, Huang QB, Fan Y and Zhang X: Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma. *Clin Cancer Res* 20(7): 1779-1790, 2014. PMID: 24486593. DOI: 10.1158/1078-0432.CCR-13-1687

- 67 Qian Z, Ren L, Wu D, Yang X, Zhou Z, Nie Q, Jiang G, Xue S, Weng W, Qiu Y and Lin Y: Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. *Int J Cancer* 140(12): 2792-2804, 2017. PMID: 28295288. DOI: 10.1002/ijc.30690
- 68 Ahn H, Kim H, Abdul R, Kim Y, Sim J, Choi D, Paik SS, Shin SJ, Kim DH and Jang K: Overexpression of forkhead box O3a and its association with aggressive phenotypes and poor prognosis in human hepatocellular carcinoma. *Am J Clin Pathol* 149(2): 117-127, 2018. PMID: 29365018. DOI: 10.1093/ajcp/aqx132
- 69 Hillion J, Le Coniat M, Jonveaux P, Berger R and Bernard OA: AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. *Blood* 90(9): 3714-3719, 1997. PMID: 9345057.
- 70 Bernard OA, Hillion J, Le Coniat M and Berger R: A new case of translocation t(6;11)(q21;q23) in a therapy-related acute myeloid leukemia resulting in an MLL-AF6q21 fusion. *Genes Chromosomes Cancer* 22(3): 221-224, 1998. PMID: 9624533.
- 71 Lee JC, Chou HC, Wang CH, Chu PY, Hsieh TH, Liu ML, Hsieh SM, Liu YR and Kao YC: Myoepithelioma-like hyalinizing epithelioid tumors of the hand with novel OGT-FOXO3 fusions. *Am J Surg Pathol* 44(3): 387-395, 2020. PMID: 31567281. DOI: 10.1097/PAS.0000000000001380
- 72 Torrence D, Zhang L, Sung YS, Dickson BC and Antonescu CR: Hyalinizing epithelioid tumors with OGT-FOXO fusions. A case report of a non-acral soft tissue mass harboring a novel FOXO4 gene rearrangement. *Genes Chromosomes Cancer* 60(7): 498-503, 2021. PMID: 33455033. DOI: 10.1002/gcc.22937
- 73 Yorozu T, Nagahama K, Morii T, Maeda D, Yoshida A, Mori T, Hayashi A and Shibahara J: Myoepithelioma-like hyalinizing epithelioid tumor of the foot harboring an OGT-FOXO1 fusion. *Am J Surg Pathol* 45(2): 287-290, 2021. PMID: 32649321. DOI: 10.1097/PAS.0000000000001539

Received July 5, 2021

Revised September 19, 2021

Accepted September 20, 2021